Vir Biotechnology Inc. reported its third quarter 2025 financial results and provided a corporate update. The company announced completion of enrollment for ECLIPSE 1 approximately two months ahead of schedule, with ECLIPSE 2 and ECLIPSE 3 studies continuing to enroll strongly. Topline data for all three studies are expected in the first quarter of 2027. Vir also plans a comprehensive data update for VIR-5500, a PSMA-targeting PRO-XTEN® dual-masked T-cell engager, in the first quarter of 2026 and has dosed the first patient in a Phase 1 study of VIR-5500 combined with androgen receptor pathway inhibitors in first-line metastatic castration-resistant prostate cancer. Financially, the company reported cash and investments of $810.7 million as of September 30, 2025, and expects its financial runway to extend into mid-2027. Selling, general and administrative expenses for the quarter were $22.2 million, down from $25.7 million in the same period in 2024, largely due to cost-saving measures. The $75.0 million milestone payment related to the VIR-5525 program was paid from escrow and did not impact the company's reported cash position or runway.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251105955316) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.